<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03363334</url>
  </required_header>
  <id_info>
    <org_study_id>C-935788-055</org_study_id>
    <nct_id>NCT03363334</nct_id>
  </id_info>
  <brief_title>Expanded Access of Fostamatinib in Patients With Persistent or Chronic Relapsing/Refractory ITP</brief_title>
  <official_title>Expanded Access (Compassionate Use) of Fostamatinib in Patients With Persistent or Chronic Relapsing/Refractory Immune Thrombocytopenic Purpura (ITP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigel Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigel Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      C-935788-055 is an open-label, multi-center, expanded access (EAP) study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the program is to provide Fostamatinib in an Expanded Access setting to
      subjects who meet the selection criteria.
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <expanded_access_info>
    <expanded_access_type_intermediate>Yes</expanded_access_type_intermediate>
  </expanded_access_info>
  <condition>Immune Thrombocytopenic Purpura</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fostamatinib disodium 100 mg</intervention_name>
    <description>Fostamatinib Disodium tablet 100 mg PO bid (morning and evening)</description>
    <other_name>Fostamatinib</other_name>
    <other_name>R935788</other_name>
    <other_name>R788</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fostamatinib disodium 150 mg</intervention_name>
    <description>Fostamatinib Disodium tablet 150 mg PO bid (morning and evening)</description>
    <other_name>Fostamatinib</other_name>
    <other_name>R935788</other_name>
    <other_name>R788</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult patient with chronic or persistent ITP.

          2. Must have failed or are unable to receive standard of care treatments for ITP.

          3. Must have at least two platelet counts &lt; 30,000/µL during the last 2 months prior to
             screen date.

        Exclusion Criteria:

          1. ITP associated with lymphoma, chronic lymphocytic leukemia, transplant, or
             thrombocytopenia associated with myeloid dysplasia.

          2. Subject has uncontrolled or poorly controlled hypertension.

          3. Any of the following laboratory abnormalities: neutrophil count of &lt; 1,500/µL, or
             transaminase levels (ALT, AST) &gt; 1.5x ULN, total bilirubin &gt; 2.0 mg/dL.

          4. Active HBV or HCV infection.

          5. Current or recent enrollment in an investigational drug or device study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Anne-Marie Duliege, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Rigel Pharmaceuticals, Inc., Chief Medical Officer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sandra Tong, M.D.</last_name>
    <phone>650-624-1100</phone>
    <email>medinfo@rigel.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Scott Henley</last_name>
    <phone>650-624-1100</phone>
    <email>shenley@rigel.com</email>
  </overall_contact_backup>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2017</study_first_submitted>
  <study_first_submitted_qc>November 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2017</study_first_posted>
  <last_update_submitted>January 5, 2018</last_update_submitted>
  <last_update_submitted_qc>January 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ITP</keyword>
  <keyword>Immune Thrombocytopenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Purpura</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

